Ron Tribble - Radiatric, Private Partnering Interview at LSI USA ‘23

Transcription

Hi, I'm Dr. Ron Tribble and I am the president, CEO of Radiatric. We are a medical device company. And we've developed some interesting technology that treats blood borne infections in a way that is non pharmacological. What we have is we've developed a very sophisticated LED technology that will be targeted at bacteria that is in the bloodstream. And the way the LED technology works is we have defined out specific wavelengths of light, that operate at very tuned frequency, and basically, intensity. And we have a treatment chamber where blood is circulated through basically like an extracorporeal device. Imagine like a dialysis machine. So blood is removed from the body, and a port goes through the device is treated in the chamber. And the way it works is by a absorption process, bacteria have certain organelles or molecules inside of them, we target one of those molecules very specifically. And that light energy we have is absorbed by the molecules. And that effectively releases free radicals, and essentially kills the bacteria. So far, we have tested three different mammalian species of blood. And all of our testing to date has shown that we do not harm any of the actual blood cells, we are targeted specifically to the bacteria, there should not be a recovery process, because we act in an entirely different mechanism than antibiotics do. So if you're dealing with antibiotics, you're finding a particular protein that you can bind to. And the reason that you have problems with recovers macrobiotics is you're essentially knocking out everything that the body has, as far as the type of bacteria, there's a lot of useful bacteria. Even if it's IV or oral, our technology is targeting this specific bacteria not harming the blood cells not harming drugs that are on board for the patient. So the recovery is really not going to be a factor, the treatment time is approximately, we envision about 90 minutes to two hours to be able to cycle a certain number of changes of the blood to go through the device and be effective. Each change in blood is going to effectively get more of the bacteria. Because if you're 90% effective the first go around, you're going to get more of them each time. So logarithmically, you're directly reducing the bacterial load, this would be primarily systemic. But a lot of times those localized infections, say you get a wound that gets staph. And before long, you could end up with a sepsis. So the design of the technology is to be used safely at any time. Because if you're not harming the patient, you're going to be able to have that suspect case that you still want to treat, where if you're dealing with antibiotics, if you have a case that you suspect sepsis, you're going to be treating that patient with antibiotics. And you're not really certain if you've chosen the right antibody line. So in some cases, you in order to decide by culture, do you have the right antibiotic, you can wait 24 to 48 hours. And if you've missed the mark, then you've missed that opportunity to treat sepsis, or that infection in early enough stage to be effective. Substance, as you're probably well aware, is one of the most leading cause for hospital acquired infections. That's the name for sepsis basically, and it is one of the largest killers of patients in the hospital. It's also one of the largest reasons for readmission to hospital. And it is one of the most costly things to treat them the hospital with not good outcomes. So we're looking at how to envision a better outcome for patient care. This is actually my first attempt to raise funds for the company. We have been completely self funded up to this point by three founders. And we have spent approximately four years working on our technology to make sure that we had something that was developed to the point where we have a working viable prototype. And we have done extensive amount of in lab testing. And we are now at the point where we're ready to go to animal studies for safety and efficacy. I just like to say that, you know, we have spent our time over a four year period making sure that our technology to the best of our knowledge, self funded works. So we're here at LSI. Now, with a plan in mind, we have a university setting shows them already to do our safety and efficacy studies. We have the protocols developed for these studies. We have our principal investigators in place ready to go So we have next stage of our development process well mapped out in place. And we are now essentially going for our first funding round. So we're looking for investors. We're also looking for strategics that might want to look at us as somebody they want to partner with at this stage to engage with us in the further development of our device.